Main Article: Take the Pain Out of Selling
| Sidebar: The Next
Big Thing Main Article: Take the Pain Out of Selling |
|
|
|
A Guest Article by Pat
McKeough
Editor and Publisher of The Successful Investor
|
This article is republished by permission from Issue # 7 of Pat McKeough's free newsletter, The McKeough Report. Where his other newsletters and their associated hotlines are subscription-based, include stock analyses and recommendations and reproduction is prohibited, The McKeough Report discusses general investing principles and is free to anyone who wants to subscribe. Information on how to subscribe to The McKeough Report and a special subscription offer for The Stock Pickers Digest follow the article.
June, 2001
A number of investors have asked me, "Now that the Internet boom has ended, what's the next big thing likely to be in the market?"
My guess is that the market's next big thing will be biotech. In fact, I'd say that in the next few years, investors will become as obsessed about health as they were obsessed about technology in the 1990s. It's a natural. As the baby boomers reach middle age and beyond, they'll inevitably become more interested in cancer and other age-related diseases, and in new ways of combating them. In addition, the medical profession is making greater strides in finding new ways to combat cancer. You've probably noticed that news from the cancer front is becoming more and more common.
Most junior biotech and health/cancer related stocks are highly speculative. That's why we only cover them in Stock Pickers Digest, our newsletter for aggressive investors.
In the July issue of Stock Pickers Digest, we introduced readers to two new junior biotechs. One is a $3.20 'Speculative' which is developing a new drug that has proven effective in tests against bladder cancer. This company is also developing a vaccine for cattle that can cut the risk of E.coli water contamination of the local water supply by 90%. (E.coli was implicated in the deaths of 21 people who died last year in Walkerton, Ontario, after drinking tainted water.) The second biotech recommendation in the July Stock Pickers Digest is a 'Startup'-rated $4.20 stock that has developed advanced tests for cholesterol and for colorectal cancer. These new tests are more accurate, cheaper and less time-consuming than existing procedures.
We plan to introduce additional junior biotech stocks to our recommendations in the August and subsequent issues of Stock Pickers Digest. If you'd like to subscribe to Stock Pickers Digest, starting with the July issue, you can do so for the special MCKEOUGH REPORT price of $138 a year, plus 7% GST (or 15% HST, if you live in NB, NF or NS). That's an 18.3% discount off the regular price of $169 a year.
To subscribe by e-mail, you cannot use the reply function on your email program. Instead, send your email subscription order to:
with your credit card number (please include expiration date) and mailing address.
Or, you can fax your subscription order to 416-756-0379, along with your credit card number. Or you can call 1-888-292-0296. Or you can mail your order with a cheque or credit card number to The Successful Investor Inc., Ste. 977, 6021 Yonge St., Toronto ON M2M 3W2. Be sure to include your email address so we can put you on the list to receive our weekly Stock Pickers Digest Hotline by email. (You can also listen to the Hotline by calling a special telephone number reserved for Stock Pickers Digest subscribers. You'll find that phone number on the front page of every issue of Stock Pickers Digest.)
To get the special rate on your Stock Pickers Digest subscription, please be sure to identify yourself as a McKeough Report subscriber. (Let him know you read it here at Investing: Canada if you're not a subscriber.)
Published
by permission
Copyright 2001 Pat McKeough
Subscribe to The McKeough Report: If you'd like to receive The McKeough Report, without cost or obligation, just send an email message to mckeoughreport@reply.net In the subject line type the word "subscribe" (without the quotation marks). The report is published periodically.